{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:06Z","timestamp":1790776446225,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-024-03096-1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:05:45Z","timestamp":1737698745000},"page":"1435-1447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-0474","authenticated-orcid":false,"given":"Shingo","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0960","authenticated-orcid":false,"given":"Bruno Casaes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-8469","authenticated-orcid":false,"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-8723","authenticated-orcid":false,"given":"Yoshiyuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-2345","authenticated-orcid":false,"given":"Hyunchung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3096_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"3096_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","volume":"21","author":"JP Segal","year":"2021","unstructured":"Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021;21:135\u20139.","journal-title":"Clin Med (Lond)"},{"key":"3096_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239\u201354.","journal-title":"J Crohns Colitis"},{"key":"3096_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00384-023-04417-6","volume":"38","author":"M Yamazaki","year":"2023","unstructured":"Yamazaki M, Chung H, Xu Y, Qiu H. Trends in the prevalence and incidence of ulcerative colitis in Japan and the US. Int J Colorectal Dis. 2023;38:135.","journal-title":"Int J Colorectal Dis"},{"key":"3096_CR5","doi-asserted-by":"publisher","first-page":"13555","DOI":"10.1038\/s41598-023-40624-5","volume":"13","author":"T Taida","year":"2023","unstructured":"Taida T, Ohta Y, Kato J, et al. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000. Sci Rep. 2023;13:13555.","journal-title":"Sci Rep"},{"key":"3096_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/25785826.2023.2195522","volume":"46","author":"H Nakase","year":"2023","unstructured":"Nakase H. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment. Immunol Med. 2023;46:121\u201330.","journal-title":"Immunol Med"},{"key":"3096_CR7","unstructured":"Japanese Ministry of Health Labour and Welfare. Ulcerative colitis\/Crohn's disease diagnostic criteria and treatment guidelines. Health, Labor and Welfare Scientific Research Grant Intractable Disease Policy Research Project, 2024."},{"key":"3096_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"3096_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/flgastro-2019-101288","volume":"12","author":"J Blackwell","year":"2021","unstructured":"Blackwell J, Selinger C, Raine T, et al. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol. 2021;12:207\u201313.","journal-title":"Frontline Gastroenterol"},{"key":"3096_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/mib.0b013e31828278a2","volume":"19","author":"GY Melmed","year":"2013","unstructured":"Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013;19:662\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"3096_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000519123","volume":"6","author":"D Bargo","year":"2021","unstructured":"Bargo D, Tritton T, Cappelleri JC, et al. Living with ulcerative colitis in Japan: biologic persistence and health-care resource use. Inflamm Intest Dis. 2021;6:186\u201398.","journal-title":"Inflamm Intest Dis"},{"key":"3096_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/ecco-jcc\/jjaa172","volume":"15","author":"K Matsuoka","year":"2021","unstructured":"Matsuoka K, Igarashi A, Sato N, et al. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021;15:358\u201366.","journal-title":"J Crohns Colitis"},{"key":"3096_CR13","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s12325-020-01615-4","volume":"38","author":"C Miyazaki","year":"2021","unstructured":"Miyazaki C, Sakashita T, Jung W, Kato S. Real-world prescription pattern and healthcare cost among patients with ulcerative colitis in Japan: a retrospective claims data analysis. Adv Ther. 2021;38:2229\u201347.","journal-title":"Adv Ther"},{"key":"3096_CR14","doi-asserted-by":"crossref","unstructured":"Horst SN, Betts KA, Nie X, Yawen Gao S, Paul D. Economic burden of suboptimal treatment with conventional therapies for ulcerative colitis [poster Su1147]. Presented at: Digestive Disease Week; May 6\u20139, 2023; Chicago, IL.","DOI":"10.1016\/S0016-5085(23)02263-1"},{"key":"3096_CR15","first-page":"53","volume":"24","author":"T Kimura","year":"2019","unstructured":"Kimura T, Sugitani T, Nishimura T, Ito M. Validation and recalibration of Charlson and Elixhauser comorbidity indices based on data from a Japanese insurance claims database. Jpn J Pharmacoepidemiol. 2019;24:53\u201364.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"3096_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022;9:175\u201387.","journal-title":"Drugs Real World Outcomes"},{"key":"3096_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227914","volume":"15","author":"A Armuzzi","year":"2020","unstructured":"Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One. 2020;15:e0227914.","journal-title":"PLoS One"},{"key":"3096_CR18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"JE Brady","year":"2018","unstructured":"Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40:1509-21.e5.","journal-title":"Clin Ther"},{"key":"3096_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40292-020-00370-5","volume":"27","author":"B Weisser","year":"2020","unstructured":"Weisser B, Predel HG, Gillessen A, et al. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and\/or dyslipidemia: results of a meta-analysis. High Blood Press Cardiovasc Prev. 2020;27:157\u201364.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"3096_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","volume":"23","author":"SV Kane","year":"2006","unstructured":"Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"3096_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000530139","volume":"8","author":"X H\u00e9buterne","year":"2023","unstructured":"H\u00e9buterne X, Vavricka SR, Thorne HC, et al. Medication formulation preference of mild and moderate ulcerative colitis patients: a European survey. Inflamm Intest Dis. 2023;8:41\u20139.","journal-title":"Inflamm Intest Dis"},{"key":"3096_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/jgh3.12796","volume":"6","author":"M Masuda","year":"2022","unstructured":"Masuda M, Fukata N, Sano Y, et al. Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice. JGH Open. 2022;6:612\u201320.","journal-title":"JGH Open"},{"key":"3096_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/apt.17039","volume":"56","author":"K Rosiou","year":"2022","unstructured":"Rosiou K, Carbonell J, Dolby V, et al. Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: the Leeds IBD Steroids study. Aliment Pharmacol Ther. 2022;56:501\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"3096_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1186\/s12913-019-4693-x","volume":"19","author":"C Nelson-Piercy","year":"2019","unstructured":"Nelson-Piercy C, Vlaev I, Harris K, Fischer-Betz R. What factors could influence physicians\u2019 management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia. BMC Health Serv Res. 2019;19:863.","journal-title":"BMC Health Serv Res"},{"key":"3096_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008597","volume":"5","author":"SL Johnson","year":"2015","unstructured":"Johnson SL, Bartels CM, Palta M, et al. Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study. BMJ Open. 2015;5:e008597.","journal-title":"BMJ Open"},{"key":"3096_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.","journal-title":"BMJ"},{"key":"3096_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158017","volume":"11","author":"AK Waljee","year":"2016","unstructured":"Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS One. 2016;11:e0158017.","journal-title":"PLoS One"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03096-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:36:56Z","timestamp":1740645416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03096-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3096"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03096-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingo Kato received honoraria from AbbVie, Janssen Pharmaceutical K.K., Kissei, Mitsubishi Tanabe, and Takeda. Bruno Casaes Teixeira, Thomas Laurent, Yoshiyuki Yamada, Kiran Dave, Shweta Shah, and Hyunchung Kim are employees and\/or shareholders of Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This real-world, retrospective, observational study used anonymized patient data from June 2018 to December 2022, obtained from Medical Data Vision, a hospital-based claims database (Medical Data Vision, Tokyo, Japan) that covers approximately 42 million patients across 474 acute care hospitals in Japan. As all data were anonymized, requirements for ethics approval and informed consent under the Ethical Guidelines for Epidemiological Research in Japan do not apply to this study. Permission was obtained to access and use data by Medical Data Vision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}